Islet cell transplantation is a cutting-edge procedure promising in treating type 1 diabetes. This innovative approach involves transferring insulin-producing islet cells from a donor pancreas to a person with type 1 diabetes, aiming to restore normal blood glucose levels and potentially reduce or eliminate the need for daily insulin injections. Let's delve into the details of islet cell transplantation, including its benefits, preparation, surgical process, risks, complications, recovery, and more.

Benefits of Islet Cell Transplantation

Islet cell transplantation offers a range of benefits for individuals with type 1 diabetes.

Restoration or improvement of the body's ability to regulaste blood sugar levels.
Reduction in the need for frequent blood sugar measurements and daily insulin injections.
Improve the quality of life by minimising episodes of low blood sugar.
Reduction in the progression of long-term complications associated with diabetes, such as heart disease, kidney disease, stroke, and nerve and eye damage.

Preparation for Islet Cell Transplantation

Candidates for islet cell transplantation typically meet the following criteria:

Between 18 and 65 years old
Have had type 1 diabetes for more than five years
Are experiencing diabetes-related complications, such as frequent episodes of unconsciousness due to lack of insulin and early signs of kidney problems

The procedure's benefits and risks are carefully weighed, and candidates must meet specific criteria to be considered suitable for transplantation.

Before the transplant, the recipient receives induction and maintenance immunosuppression in the hospital, along with intensive insulin therapy targeting normoglycemia. It "rests" the islets at the time of transplantation when the isolation procedure has stressed them, and they are devascularised and susceptible to glucotoxicity.

The timing of induction agents and islet culture time may vary, but in one study, the T lymphocyte–depleting polyclonal antibody thyroglobulin was initiated with a standard 1.5 mg/kg dose divided as 0.5 mg/kg on day −2 and 1.0 mg/kg on day −1, with additional 1.5 mg/kg doses on days 0, 1, and 2 when tolerated per prescribing guidelines.

Surgical Process of Islet Cell Transplantation

The surgical process of islet cell transplantation involves the following steps.

Islet cells are isolated from a deceased donor's pancreas. The pancreas is processed in a machine that extracts and purifies the islet cells.
To promote their survival, the isolated islet cells are suspended in a solution containing heparin and other compounds. The volume of islet cells does not exceed 5 ml.
The recipient is prepared by receiving induction immunosuppression medications to prevent rejection of the transplanted islet cells. Intensive insulin therapy is also given to "rest" the islets at the time of transplantation.
Using image guidance, such as ultrasound or fluoroscopy, the islet cell solution is infused into the recipient's portal vein in the liver through a catheter. This can be done through a small incision under general anaesthesia.
The infusion takes approximately 15 minutes. The portal vein pressure is monitored and kept below 22 mmHg. Once complete, the catheter is removed, and the vein is sealed.
After transplantation, the islet cells begin to release insulin soon after. However, it takes time for the islets to become fully functional and establish a blood supply. Insulin is usually given until the transplanted islets are working correctly.

Islet cell transplantation, a promising treatment for type 1 diabetes, carries several risks and complications, both short-term and long-term.

Short-term Risks

Bleeding: Accessing the portal vein via the percutaneous hepatic approach carries the risk of bleeding.
Portal Vein Thrombosis: Infusing islets carries a risk of portal vein thrombosis.
Elevation of Serum Cholesterol and Blood Pressure: Some patients may experience an elevation of serum cholesterol and blood pressure.
Decline in Renal Function: In some cases, there has been a decline in renal function.
Acute Retinal Bleeds: A few patients have experienced acute retinal bleeds.

Long-term Risks

Malignancy: Longer-term risks include malignancy, which is rare in clinical islet transplantation.
Severe Infection: Serious infection is another rare but possible long-term risk.
Sensitisation to Donor Antigens: Sensitisation to donor antigens may also occur.
Immunosuppression Side Effects: Common minor problems with immunosuppression include mouth ulcers, diarrhoea, and acne.
Rejection: The immune system may reject the transplanted islets, which can lead to a loss of function.
Infections and Cancers: Immunosuppressive medications can put the person at risk for infections and certain cancers.
Side Effects: These medications can also cause side effects that range from mild to severe.

Recovery after Islet Transplant

After islet cell transplantation, recipients undergo a period of recovery and are closely monitored for any signs of rejection or complications.

Recipients are typically in the Intensive Care Unit for up to 24 hours after surgery, as the transplant team monitors vital signs and checks for complications.
If the recipient had a simultaneous kidney transplant, they may need dialysis as the new kidneys begin to function.
The recipient remains in the hospital for up to one to two weeks after surgery.
Physical therapy is provided to build body strength, and nutritional counselling is given to avoid weight gain associated with anti-rejection medications.
Outpatient testing includes blood tests, abdominal imaging tests, and occasional biopsies to check for rejection.

Islet cell transplantation represents a promising avenue in the management of type 1 diabetes, offering hope for improved glycaemic control, reduced reliance on insulin therapy, and enhanced quality of life for individuals living with this chronic condition. As research continues to advance, the future of islet cell transplantation holds the potential to revolutionise diabetes treatment and provide new avenues for those seeking alternative therapies for managing their condition.

Frequently Asked Questions About Islet Cell Transplantation

Q. What is islet cell transplantation?
A: Islet cell transplantation involves transferring insulin-producing cells (islets) from a donor pancreas into the body of a person with type 1 diabetes.

Q. How does islet cell transplantation benefit people with diabetes?
A: Islet cell transplantation can improve blood sugar control and reduce the need for insulin injections, potentially leading to better quality of life and fewer diabetes-related complications.

Q. Who is a candidate for islet cell transplantation?
A: Candidates for islet cell transplantation typically have type 1 diabetes with severe hypoglycemia unawareness or have difficulty managing blood sugar levels despite optimal medical therapy.

Q. What are the risks associated with islet cell transplantation?
A: Risks include the need for immunosuppressive medications to prevent rejection of the transplanted cells, which can increase the risk of infections and other side effects. There is also a risk that the transplanted cells may not function effectively for a long time.

Q. What is the success rate of islet cell transplantation?
A: Success rates vary, but many recipients experience improved blood sugar control and quality of life following islet cell transplantation. Ongoing research aims to enhance the procedure's effectiveness and durability.